Prognostic Value of the Lung Immune Prognostic Index for Metastatic Non-Small Cell Lung Cancer Patients: A Chinese Cohort Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non–small-cell lung cancer: US food and drug administration trial-level and patient-level analyses. J Clin Oncol. 2015;33(9):1008–1014. doi:10.1200/JCO.2014.59.0489
   PubMed Web of Science ®Google Scholar
• Zhan P, Zhang B, Xi G-M, et al. PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway. Mol Cancer. 2017;16(1):108. doi:10.1186/s12943-017-0682-z
   PubMedGoogle Scholar
• Conlon C, Pupa L, Reece EM, et al. When benign becomes cancer: malignant degeneration of chronic inflammation. Semin Plast Surg. 2021;35(3):159–163. doi:10.1055/s-0041-1731462
   Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349
   PubMed Web of Science ®Google Scholar
• Sprooten J, De Wijngaert P, Vanmeerbeek I, et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells. 2020;9(8):1823. doi:10.3390/cells9081823
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–249. doi:10.1146/annurev-pathol-042020-042741
   PubMed Web of Science ®Google Scholar
• Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013;30:S48–S57. doi:10.1016/j.bbi.2012.06.011
   PubMed Web of Science ®Google Scholar
• Bower JE. The role of neuro-immune interactions in cancer-related fatigue: biobehavioral risk factors and mechanisms. Cancer. 2019;125(3):353–364. doi:10.1002/cncr.31790
   PubMed Web of Science ®Google Scholar
• Baazim H, Antonio-Herrera L, Bergthaler A. The interplay of immunology and cachexia in infection and cancer. Nat Rev Immunol. 2022;22(5):309–321. doi:10.1038/s41577-021-00624-w
   PubMed Web of Science ®Google Scholar
• Moro-García MA, Mayo JC, Sainz RM, et al. Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes. Front Immunol. 2018;9:339. doi:10.3389/fimmu.2018.00339
   PubMed Web of Science ®Google Scholar
• Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425–6440. doi:10.1002/jcp.26429
   PubMed Web of Science ®Google Scholar
• Milanovic N, Matkovic S, Ristic D, et al. Significance of tumor burden, vascular endothelial growth factor, lactate dehydrogenase and beta-2 microglobulin serum levels in advanced diffuse large B cell lymphoma. J BUON. 2012;17(3):497–501.
   Web of Science ®Google Scholar
• Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353–363. doi:10.3233/CBM-160336
   PubMed Web of Science ®Google Scholar
• Claus M, Dychus N, Ebel M, et al. Measuring the immune system: a comprehensive approach for the analysis of immune functions in humans. Arch Toxicol. 2016;90(10):2481–2495. doi:10.1007/s00204-016-1809-5
   Web of Science ®Google Scholar
• Kazandjian D, Gong Y, Keegan P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non–small cell lung cancer. JAMA Oncol. 2019;5(10):1481. doi:10.1001/jamaoncol.2019.1747
   PubMed Web of Science ®Google Scholar
• Mezquita L, Auclin E, Ferrara R, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol. 2018;4(3):351. doi:10.1001/jamaoncol.2017.4771
   PubMed Web of Science ®Google Scholar
• Russo A, Russano M, Franchina T, et al. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study. Adv Ther. 2020;37(3):1145–1155. doi:10.1007/s12325-020-01229-w
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Ascierto PA, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016;27(4):732–738. doi:10.1093/annonc/mdw016
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Komuta K. Pretreatment Lung immune prognostic index is a prognostic marker of chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor. World J Oncol. 2019;10(1):35–45. doi:10.14740/wjon1179
   PubMedGoogle Scholar
• Shi Y, Li J, Zhang S, et al. Molecular epidemiology of EGFR Mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - Mainland China Subset analysis of the PIONEER study. PLoS One. 2015;10(11):e0143515. doi:10.1371/journal.pone.0143515
   PubMed Web of Science ®Google Scholar
• Gelatti A, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113–122. doi:10.1016/j.lungcan.2019.09.017
   PubMed Web of Science ®Google Scholar
• Huang L, Han H, Zhou L, et al. Evaluation of the lung immune prognostic index in non-small cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis. Front Oncol. 2021;11:670230. doi:10.3389/fonc.2021.670230
   Google Scholar
• Lee SY, Lee SI, Min B-W, et al. Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer. Ann Surg Treat Res. 2021;100(1):25–32. doi:10.4174/astr.2021.100.1.25
   Web of Science ®Google Scholar
• Cho U, Park HS, Im SY, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;13(7):e0200936. doi:10.1371/journal.pone.0200936
   PubMed Web of Science ®Google Scholar
• Ghobadi H, Mohammadshahi J, Javaheri N, et al. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients. Front Med. 2022;9:916453. doi:10.3389/fmed.2022.916453
   Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059
   PubMed Web of Science ®Google Scholar
• Alessi JV, Ricciuti B, Alden SL, et al. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer. 2021;9(11):11. doi:10.1136/jitc-2021-003536
   Web of Science ®Google Scholar
• Delikgoz SE, Kemal Y, Karacin C, et al. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy. J Med Imaging Radiat Oncol. 2022;66(1):146–157. doi:10.1111/1754-9485.13341
   Web of Science ®Google Scholar
• Yun NK, Rouhani SJ, Bestvina CM, et al. Neutrophil-to-lymphocyte ratio is a predictive biomarker in patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) therapy. Cancers. 2021;13(6):1426. doi:10.3390/cancers13061426
   PubMed Web of Science ®Google Scholar
• Xu C, Yao X, Li T, et al. Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR-mutant Non-small cell lung cancer. Transl Cancer Res. 2020;9(4):2875–2883. doi:10.21037/tcr.2020.02.28
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7. doi:10.1016/j.lungcan.2017.01.013
   PubMed Web of Science ®Google Scholar
• Nakaya A, Kurata T, Yoshioka H, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol. 2018;23(4):634–640. doi:10.1007/s10147-018-1250-2
   PubMed Web of Science ®Google Scholar
• Pan Y, Si H, Jia R, et al. Analysis of a systemic inflammatory biomarker in advanced bile tract carcinoma treated with anti-PD-1 therapy: prognostic and predictive significance of lung immune prognostic index score. J Oncol. 2022;2022:1427779. doi:10.1155/2022/1427779
   Web of Science ®Google Scholar
• Kiriu T, Yamamoto M, Nagano T, et al. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer. PLoS One. 2018;13(2):e0193018. doi:10.1371/journal.pone.0193018
   PubMed Web of Science ®Google Scholar
• Forkasiewicz A, Dorociak M, Stach K, et al. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25:35. doi:10.1186/s11658-020-00228-7
   PubMed Web of Science ®Google Scholar
• Claps G, Faouzi S, Quidville V, et al. The multiple roles of LDH in cancer. Nat Rev Clin Oncol. 2022;19(12):749–762. doi:10.1038/s41571-022-00686-2
   PubMed Web of Science ®Google Scholar
• Seth P, Csizmadia E, Hedblom A, et al. Deletion of lactate dehydrogenase-A in myeloid cells triggers antitumor immunity. Cancer Res. 2017;77(13):3632–3643. doi:10.1158/0008-5472.CAN-16-2938
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961–970. doi:10.3109/0284186X.2015.1043026
   PubMed Web of Science ®Google Scholar